Stifel: Maintaining the MEI Pharma (MEIP.US) rating, adjusted from holding to holding rating, and adjusting the target price from $7.00 to $7.00.

Stifel: Maintaining the MEI Pharma (MEIP.US) rating, adjusted from holding to holding rating, and adjusting the target price from $7.00 to $7.00.

Zhitong FinanceApr 12 23:50

Stifel Maintains Hold on MEI Pharma, Maintains $7 Price Target

Stifel analyst Stephen Willey maintains MEI Pharma (NASDAQ:MEIP) with a Hold and maintains $7 price target.

BenzingaApr 12 23:49

MEI Pharma Shelves Plans for a Second Return of Capital

Seeking AlphaApr 12 02:17

MEI Pharma Aligns On Strategy To Advance Voruciclib And ME-344

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritiz

BenzingaApr 11 20:06

MEI Pharma Reports Initial Data From Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients

– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study –– ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity

BenzingaApr 11 20:05

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.

BusinesswireApr 10 20:00